1. Shanghai investigation finds safety signals were not acted on before a child's death in a gene-editing study
Shanghai authorities on 13 November released the findings of an investigation into a gene-editing study at Xinhua Hospital, in which a six-year-old girl with Snijders Blok-Campeau syndrome died on 31 March 2025, seven days after receiving the experimental treatment; the hospital's ethics committee attributed the death to thrombotic microangiopathy, a complication of gene therapy. Investigators found that the preclinical team did not promptly pass safety findings from non-human primate studies to the clinical study lead, so warning signals in the safety report did not receive due attention, and that neither those findings nor the death were disclosed when the work was published in Nature in February 2026. The ethics committee had approved the study despite insufficient toxicology and safety evidence, and the consent form did not specifically highlight the risk of death; two researchers were dismissed and barred from research programmes for five years, and Shanghai has launched special inspections of clinical research into new biomedical technologies. For sponsors and investigators in cell and gene therapy, the case shows why nonclinical safety findings must reach the clinical team and the ethics committee before first dosing, and why serious outcomes must be disclosed in publications. Global Times, 13 Nov 2026
2. EU: DHPC on tirzepatide (Mounjaro) and the reliability of oral contraceptives
At its November meeting, EMA's CHMP adopted a direct healthcare professional communication on the potential effect of Mounjaro (tirzepatide) on the reliability of oral contraceptives. The DHPC notes that limited information is available on the effect of tirzepatide on the pharmacokinetics and efficacy of oral contraceptives in women with obesity, overweight or type 2 diabetes; women using an oral contraceptive are advised to add a barrier method for 4 weeks after starting tirzepatide and for 4 weeks after each dose increase, or to switch to a non-oral method. The DHPC will be sent by the marketing authorisation holder after a European Commission decision. For safety teams, the advice targets initiation and each dose increase, and it is a reminder to capture contraceptive use and follow up any pregnancies reported during treatment. EMA CHMP highlights, 13 Nov 2026
3. EMA confirms procedures to add NAION to Mounjaro and Trulicity product information
In a written reply to the Portuguese news agency Lusa on 13 November, EMA said procedures are under way to add information on non-arteritic anterior ischaemic optic neuropathy (NAION) to the product information of Mounjaro (tirzepatide) and Trulicity (dulaglutide). For Mounjaro, the proposal is to state that NAION cases have been observed with GLP-1 receptor agonist medicines, based on clinical trial and post-marketing data; for Trulicity, the proposed change is based on pharmacovigilance data and the scientific literature. The changes still require European Commission approval; NAION is already listed in the EU as a very rare adverse reaction of semaglutide. This follows FDA's class-wide labelling requirement of 9 November, and companies with GLP-1-based products should note that EU wording and timelines may differ from the US. Observador (Lusa), 13 Nov 2026
4. FDA issues a complete response letter for ivonescimab in EGFR-mutated lung cancer on benefit-risk grounds
Summit Therapeutics announced on 15 November that FDA issued a complete response letter for ivonescimab, a PD-1 x VEGF bispecific antibody, in combination with platinum-containing chemotherapy for EGFR-mutated, locally advanced or metastatic non-small cell lung cancer after EGFR tyrosine kinase inhibitor therapy. According to the company, FDA determined that substantial evidence of effectiveness was not established without a statistically significant overall survival improvement, and that the progression-free survival benefit alone did not support a positive benefit-risk profile. The HARMONi trial met its progression-free survival endpoint but not overall survival; the company cites a post-hoc analysis with a hazard ratio of 0.76. For benefit-risk teams, the decision shows that a progression-free survival gain without an overall survival benefit may not be enough for FDA to conclude that benefits outweigh risks in this setting. Summit Therapeutics press release, 15 Nov 2026
This news brief is for information only and is not medical or regulatory advice. Source links open the original publication in a new tab.
Follow Safety Strategy on LinkedIn (opens in a new tab) for updates. All news briefs · News and articles